相关临床试验
4
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
75.0%
已完成
1
25.0%
暂无批准数据
- Kelun-Biotech successfully completed a $250 million share placement on June 5, 2025, representing the largest follow-on offering in Hong Kong's biopharma sector over the past 12 months. - The offering was multiple times oversubscribed with strong participation from global institutional investors, leading to an upsize from the initially targeted $200 million. - Proceeds will fund R&D, clinical trials, manufacturing and commercialization of the company's innovative drug pipeline, which includes over 30 ongoing projects and a leading ADC platform. - The company focuses on solid tumors, autoimmune, inflammatory and metabolic diseases, with 3 approved products, 1 in NDA stage, and over 10 in clinical development.
- Kelun-Biotech's SKB445, a novel antibody-drug conjugate (ADC), has been approved by China's NMPA for clinical trials in advanced solid tumors. - SKB445 leverages Kelun-Biotech's OptiDC platform, demonstrating promising preclinical efficacy and a favorable safety profile. - The drug targets unmet medical needs in solid tumors, marking a significant step in Kelun-Biotech's globalized drug development strategy. - This approval underscores Kelun-Biotech's focus on innovative biological drugs and small molecule drugs for major disease areas.
